The British Business Bank has made its largest funding commitment to date, investing £100 million in Apposite Healthcare Growth I. This is the Bank’s first investment with Apposite Capital and is intended to help the fund achieve its first close and attract more private capital. The goal is to support a part of the UK market where funding shortages have caused promising companies to move abroad.
Apposite Healthcare Growth I will invest in companies working in medical products, diagnostics, life sciences tools, digital health, and pharmaceutical outsourcing. The fund targets businesses that have moved past early development but still need more funding to expand and compete globally.
In 2025, the UK remained Europe’s top biotech market, making up 30% of all European venture funding. Still, UK biotech venture capital deals dropped by 13% from 2024. Without sufficient late-stage funding at home, many companies seek overseas investors or sell early at lower valuations.
The Bank’s investment in Apposite is part of a bigger strategy. It plans to allocate more than 60% of its venture and growth investments to scale-ups and aims to launch 10 new growth-stage funds over the next five years.
The fund supports last year’s Life Sciences Sector Plan, which is the government’s effort to make the UK Europe’s top life sciences hub by 2030. Apposite is also working with the National Institute for Health and Care Research, which has a yearly budget of £1.7 billion, to increase the fund’s impact.
Since 2006, Apposite has focused on healthcare and life sciences, building a solid record in European healthcare investments. The new Apposite Healthcare Growth I fund is a dedicated growth-stage fund for companies that need bigger investments to expand.
